Caprelsa (vandetanib): Restriction of indication
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Caprelsa
|
Active substance |
Vandetanib
|
Therapeutic area (MeSH) |
Thyroid Neoplasms
|
Procedure number |
EMEA/H/C/002315/II/0043
|
Regulatory outcome |
Variation
|
DHPC type |
Restriction of indication
|
Human ATC code |
L01XE
|